Abstract
Alzheimers disease (AD) is the most prevalent neurodegenerative disease in the growing population of elderly people. A characteristic of AD is the accumulation of plaques in the brain of AD patients, and theses plaques mainly consist of aggregates of amyloid β-peptide (Aβ). All converging lines of evidence suggest that progressive accumulation of the Aβ plays a central role in the genesis of Alzheimers disease and it was long understood that Aβ had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. This process could be modulated by molecular chaperones which inhibit or accelerate the amyloid formation. The enzyme Acetylcholinesterase (AChE) induces Aβ fibrils formation, forming a stable complex highly neurotoxic. On the other hand, laminin inhibit the Aβ fibrils formation and depolymerizate Aβ fibrils also. Over the past decade, data have emerged from the use of several sources of Aβ (synthetic, cell culture, transgenic mice and human brain) to suggest that intermediate species called Aβ oligomers are also injurious. Accumulating evidence suggests that soluble forms of Aβ are indeed the proximate effectors of synapse loss and neuronal injury. On the other hand, the member of the Wnt signaling pathway, β-catenin was markedly reduced in AD patients carrying autosomal dominant PS-1. Also, neurons incubated with Aβ revealed a significant dose-dependent decrease in the levels of cytosolic β-catenin an effect which was reversed in cells co-incubated with increasing concentrations of lithium, an activator of Wnt signaling pathway. Wnt signaling blocks the behavioural impairments induced by hippocampal injection of Aβ, therefore the activation of Wnt signaling protects agains the Aβ neurotoxicity. Here we review recent progress about Aβ structure and function, from the formation of amyloid fibrils and some molecular chaperones which modulate the amyloidogenesic process to synaptic damage induce by Aβ oligomers.
Keywords: Alzheimer's disease, senile plaque, amyloid β-peptide, neurodegeneration, synaptic toxicity, amyloid oligomers, acetylcholinesterase, Wnt-signaling pathway
Current Alzheimer Research
Title: Structure-Function Implications in Alzheimers Disease: Effect of Aβ Oligomers at Central Synapses
Volume: 5 Issue: 3
Author(s): Waldo Cerpa, Margarita C. Dinamarca and Nibaldo C. Inestrosa
Affiliation:
Keywords: Alzheimer's disease, senile plaque, amyloid β-peptide, neurodegeneration, synaptic toxicity, amyloid oligomers, acetylcholinesterase, Wnt-signaling pathway
Abstract: Alzheimers disease (AD) is the most prevalent neurodegenerative disease in the growing population of elderly people. A characteristic of AD is the accumulation of plaques in the brain of AD patients, and theses plaques mainly consist of aggregates of amyloid β-peptide (Aβ). All converging lines of evidence suggest that progressive accumulation of the Aβ plays a central role in the genesis of Alzheimers disease and it was long understood that Aβ had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. This process could be modulated by molecular chaperones which inhibit or accelerate the amyloid formation. The enzyme Acetylcholinesterase (AChE) induces Aβ fibrils formation, forming a stable complex highly neurotoxic. On the other hand, laminin inhibit the Aβ fibrils formation and depolymerizate Aβ fibrils also. Over the past decade, data have emerged from the use of several sources of Aβ (synthetic, cell culture, transgenic mice and human brain) to suggest that intermediate species called Aβ oligomers are also injurious. Accumulating evidence suggests that soluble forms of Aβ are indeed the proximate effectors of synapse loss and neuronal injury. On the other hand, the member of the Wnt signaling pathway, β-catenin was markedly reduced in AD patients carrying autosomal dominant PS-1. Also, neurons incubated with Aβ revealed a significant dose-dependent decrease in the levels of cytosolic β-catenin an effect which was reversed in cells co-incubated with increasing concentrations of lithium, an activator of Wnt signaling pathway. Wnt signaling blocks the behavioural impairments induced by hippocampal injection of Aβ, therefore the activation of Wnt signaling protects agains the Aβ neurotoxicity. Here we review recent progress about Aβ structure and function, from the formation of amyloid fibrils and some molecular chaperones which modulate the amyloidogenesic process to synaptic damage induce by Aβ oligomers.
Export Options
About this article
Cite this article as:
Cerpa Waldo, Dinamarca C. Margarita and Inestrosa C. Nibaldo, Structure-Function Implications in Alzheimers Disease: Effect of Aβ Oligomers at Central Synapses, Current Alzheimer Research 2008; 5 (3) . https://dx.doi.org/10.2174/156720508784533321
DOI https://dx.doi.org/10.2174/156720508784533321 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Abnormal Functional and Structural Asymmetry as Biomarker for Schizophrenia
Current Topics in Medicinal Chemistry Modulation of the Ceramide Level, A Novel Therapeutic Concept
Current Drug Targets Annexins in the Central Nervous System: Are they Neuroprotective or Proapoptotic Agents?
Medicinal Chemistry Reviews - Online (Discontinued) Editorial (Thematic Issue: Disease Control and Active and Healthy Ageing: New Paradigms of Therapeutic Strategy)
Current Pharmaceutical Design Alzheimer’s Disease: Physical Activities as an Effective Intervention Tool - A Mini-Review
Current Alzheimer Research Sphingosine 1-Phosphate in Vascular Biology: Possible Therapeutic Strategies to Control Vascular Diseases
Current Pharmaceutical Design Synthesis of Novel 4-(Dimethylaminoalkyl)piperazine-1-carbodithioa t e Derivatives as Cholinesterase Inhibitors
Letters in Drug Design & Discovery Inhalational Anesthetic Sevoflurane Rescues Retina Function in Alzheimer’s Disease Transgenic Drosophila
Current Alzheimer Research Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities
Current Pharmaceutical Design Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement: Meta-Analysis of Clinical Outcomes and Cost-Effectiveness
Current Pharmaceutical Design Editorial [Hot Topic: G-Protein-Coupled Receptors (GPCRs) and Drug Discovery (Guest Editor: Luca Gentilucci)]
Current Drug Targets Chitosan Nanoparticles: An Approbative System for the Delivery of Herbal Bioactives
The Natural Products Journal Obstructive Sleep Apnea as an Independent Stroke Risk Factor: Possible Mechanisms
Current Molecular Medicine Autonomic Sudomotor Dysfunction in Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Interaction of Buffalo Brain Cystatin with Serotonin
Current Nanoscience Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Targeting Microglial Polarization to Improve TBI Outcomes
CNS & Neurological Disorders - Drug Targets Targeting Functional Biomarkers in Schizophrenia with Neuroimaging
Current Pharmaceutical Design Synthesis and Biological Activities of Naturally Functionalized Polyamines: An Overview
Current Medicinal Chemistry Molecular Basis for the Neuroprotective Properties of FKBP-Binding Immunophilin Ligands
Current Medicinal Chemistry - Central Nervous System Agents